ALEC Alector, Inc. - Fundamental Analysis
BEARISH
Sign in to save
Save this symbol to a watchlist or track a position.
ALEC Stock | Fundamental Analysis & Investment Insights
NASDAQ
Healthcare
Biotechnology
Current Price
Live
$2.2
Analyst Target
$2.88
+30.9%
Upside
52W High
$3.4
52W Low
$0.87
At a glance
Key valuation, profitability, growth, and risk metrics.
AI Analysis
Powered by advanced machine learning algorithms
Confidence Score
85%
Analysis Accuracy
ALEC's Advanced Deterministic Scorecard reveals significant financial distress: a Piotroski F-Score of 4/9 indicates weak operational health, and the absence of an Altman Z-Score (with a Debt/Equity of 1.18 and negative ROE/ROA) raises bankruptcy risk concerns. Despite a recent 1Y return of +53.9%, the stock trades at extreme valuation multiples (Price/Sales 11.54, Price/Book 7.91) with no profitability, negative earnings, and a staggering -88.5% YoY revenue decline. Insider selling of $0.49M over six months, including large sales by top executives, signals poor confidence. The analyst consensus of 'hold' reflects cautious optimism, but the fundamental deterioration and lack of sustainable value drivers suggest limited upside.
Key Strengths
Recent quarterly earnings have consistently beaten estimates (3/4 in last 4 quarters)
Average earnings surprise of 19.79% in the last four quarters indicates strong execution on guidance
High current and quick ratios (3.83 and 3.68) suggest strong short-term liquidity
Positive momentum in 1-month and 1-week price performance (+14.6% and +10.0%)
Analyst target price of $2.88 implies a modest upside from current levels
Key Risks
Piotroski F-Score of 4/9 indicates weak financial health and operational stability
Negative ROE (-181.56%) and ROA (-25.13%) reflect severe capital inefficiency
Revenue has collapsed by 88.5% YoY, signaling fundamental business deterioration
Insiders have sold $0.49M in shares over 6 months, including top executives, indicating bearish sentiment
No Graham Number or intrinsic value estimate, and no dividend, making valuation purely speculative
Performance Snowflake
Multi-dimensional AI analysis across 5 key categories
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Historical Performance Trends
Long-term financial metrics and growth patterns
Valuation Metrics
Key valuation ratios and pricing indicators
Profitability, Growth & Financial Health
Detailed profit margins, ROE, debt ratios, and liquidity metrics
Sector Comparison & Peer Analysis
Compare ALEC against industry averages and similar companies
Insider Trading & Analyst Ratings
Track insider transactions and Wall Street analyst recommendations
Past News Coverage
Recent headlines mentioning ALEC from our newsroom.
Newest → oldest
No matching news yet.